Lv1
40 积分 2026-01-09 加入
AML-626: Real-World Safety Profile of Isocitrate Dehydrogenase (IDH)-1 Inhibitors: A Pharmacovigilance Comparison of Olutasidenib and Ivosidenib Utilizing the FDA Adverse Event Reporting System (FAERS)
13小时前
已关闭
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy
14小时前
已关闭
Safety and efficacy of ivosidenib in the treatment of isocitrate dehydrogenase 1 mutant cholangiocarcinoma and acute myeloid leukemia: a systematic review and meta-analysis
14小时前
已完结
Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial
14小时前
已完结
皖公网安备34019202002308
